ARB-202 is under clinical development by Arbele and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ARB-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ARB-202 overview

ARB-202 is under development for the treatment of refractory pancreatic cancer, refractory bile duct cancer (cholangiocarcinoma), stomach cancer, gastrointestinal tumor, liver, colorectal  and colon cancer. It is a bi-specific monoclonal antibody acts by targeting CDH17/CD3 (cadherin-17/CD3).

Arbele overview

Arbele is a biopharmaceutical company that discovers and develops immunotherapeutics for the treatment of cancers, immune disorders and neurological diseases. Arbele is headquartered in Hong Kong.

For a complete picture of ARB-202’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.